<DOC>
	<DOCNO>NCT01837095</DOCNO>
	<brief_summary>POL6326 give i.v . infusion 2 hour . Treatment occur day prior , day day treatment eribulin . Different dos dose frequency investigate</brief_summary>
	<brief_title>Dose Escalation POL6326 Combination With Eribulin Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologically confirm invasive cancer breast . Presence least one measurable lesion per RECIST 1.1 criterion Stage IV disease AJCC criterion ( 7th edition ) . HER2 negative ( IHC 0,1 FISH HER2 : CEP17 ratio &lt; 2.0 ) Must treatment least 2 3 previous regimen metastatic setting . Previous treatment must include anthracycline taxane either adjuvant metastatic setting . At least 21 day completion previous cytotoxic chemotherapy biological therapy time initiation POL6326 . ECOG performance status &lt; 2 Previously receive eribulin . Peripheral neuropathy &gt; Grade 2 . Receipt investigational agent within 28 day prior Day 1 . Receipt colony stimulate factor filgrastim , pegfilgrastim , sargramostim within 14 day prior Day 1 . Radiation therapy within 14 day prior Day 1 . Severe concurrent illness psychiatric illness/social situation would limit compliance study requirement . History malignancy â‰¤ 5 year previous exception basal cell squamous cell carcinoma skin treat local resection carcinoma situ cervix . Pregnant breastfeeding . Known HIV positivity combination antiretroviral therapy ; patient increase risk lethal infection treat marrowsuppressive therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Overall survival</keyword>
	<keyword>Progression free survival</keyword>
</DOC>